To assay OAS2 as a potential therapeutic biomarker, we analyzed a public microarray dataset of a dose-response and time-course study on psoriasis treatment by analyzing the transcriptional level of skin biopsy after anti-IL-17R (brodalumab) treatment (25). Here, OAS2 is linked to psoriasis.